Literature DB >> 24414303

Dramatic remission of nephrotic syndrome after unusual complication of mucormycosis in idiopathic membranous nephropathy.

Wenling Ye1, Yingyi Wang, Yubing Wen, Hang Li, Xuemei Li.   

Abstract

Mucormycosis is a rare and fatal opportunistic infection occurring in severely immunocompromised patients. Here, we report, for the first time, on a 65-year-old man with idiopathic membranous nephropathy and moderate renal dysfunction who suffered from life-threatening pulmonary mucormycosis during immunosuppressive therapy. After amphotericin B (AmB) administration with a total accumulating dose of 1.5 g, not only has he recovered from this fatal infection, but also his nephrotic syndrome has entered complete and long-term remission without any continued corticosteroid and immunosuppressive therapy during the 6-year follow-up. Serum creatinine levels remained stable by adjusting the tolerable daily dose of AmB during the period of treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24414303     DOI: 10.1007/s11255-013-0628-3

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  28 in total

Review 1.  Pulmonary mucormycosis.

Authors:  Georgios Hamilos; George Samonis; Dimitrios P Kontoyiannis
Journal:  Semin Respir Crit Care Med       Date:  2011-12-13       Impact factor: 3.119

2.  Cytokine responses and regulation of interferon-gamma release by human mononuclear cells to Aspergillus fumigatus and other filamentous fungi.

Authors:  Adilia Warris; Mihai G Netea; Paul E Verweij; Peter Gaustad; Bart-Jan Kullberg; Corry M R Weemaes; Tore G Abrahamsen
Journal:  Med Mycol       Date:  2005-11       Impact factor: 4.076

3.  Fibrillary glomerulonephritis complicated by membranous nephropathy in a patient with tuberculosis.

Authors:  Xueguang Liu; Hong Liu; Zhonghua Zhao; Zhigang Zhang; Xiaoqiang Ding
Journal:  Int Urol Nephrol       Date:  2012-07-24       Impact factor: 2.370

4.  Long-term outcome and prognostic factors of idiopathic membranous nephropathy in the Chinese population.

Authors:  Ke Zuo; Yan Wu; Shi-Jun Li; Feng Xu; Cai-Hong Zeng; Zhi-Hong Liu
Journal:  Clin Nephrol       Date:  2013-06       Impact factor: 0.975

Review 5.  Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials.

Authors:  Yizhi Chen; Arrigo Schieppati; Guangyan Cai; Xiangmei Chen; Javier Zamora; Giovanni A Giuliano; Norbert Braun; Annalisa Perna
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-28       Impact factor: 8.237

6.  Allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia and pulmonary mucormycosis.

Authors:  D Schneidawind; D Nann; W Vogel; C Faul; F Fend; M Horger; L Kanz; W Bethge
Journal:  Transpl Infect Dis       Date:  2012-10-17       Impact factor: 2.228

Review 7.  Immunosuppressive treatment of idiopathic membranous nephropathy: the dilemma continues.

Authors:  Edward J Filippone
Journal:  Clin Nephrol       Date:  2013-02       Impact factor: 0.975

8.  Rhinocerebral mucormycosis acquired after a short course of prednisone therapy.

Authors:  Angela D Ferguson
Journal:  J Am Osteopath Assoc       Date:  2007-11

9.  Interleukin-22 mediates early host defense against Rhizomucor pusilluscan pathogens.

Authors:  Wei Bao; Lei Jin; Hai-jing Fu; Yong-nian Shen; Gui-xia Lu; Huan Mei; Xin-zhi Cao; Hong-sheng Wang; Wei-da Liu
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

10.  Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.

Authors:  Andrew Howman; Tracey L Chapman; Maria M Langdon; Caroline Ferguson; Dwomoa Adu; John Feehally; Gillian J Gaskin; David R W Jayne; Donal O'Donoghue; Michael Boulton-Jones; Peter W Mathieson
Journal:  Lancet       Date:  2013-01-09       Impact factor: 79.321

View more
  1 in total

1.  Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome.

Authors:  Jun Feng; Xuefeng Sun
Journal:  Infection       Date:  2018-05-10       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.